American Medical Association statement on antibody treatments

Community NewsNews
294

Translate to Spanish or other 102 languages!

We are pleased that the FDA is following the scientific evidence and limiting the use of monoclonal antibody treatments to those that are effective against the Omicron variant. Image for illustration purposes.
We are pleased that the FDA is following the scientific evidence and limiting the use of monoclonal antibody treatments to those that are effective against the Omicron variant. Image for illustration purposes.

Mega Doctor News

- Advertisement -

Gerald E. Harmon, M.D.
President, American Medical Association

“Given the latest data showing the Omicron variant of SARS-CoV-2 is responsible for 99% of current COVID-19 infections, we are pleased that the FDA is following the scientific evidence and limiting the use of monoclonal antibody treatments to those that are effective against the Omicron variant. Limiting the use of these treatments will help ensure patients receive the best available therapy. We encourage physicians to reference the current National Institutes of Health (NIH) COVID-19 treatment guidelines for the latest information on authorized therapies and recommendations for their use.

“We continue to strongly urge every eligible individual to make sure they are up to date on their COVID-19 vaccinations, including booster doses. The Omicron variant is highly contagious and the unvaccinated remain most at risk of severe illness, hospitalization and death if infected. Data further suggests that a booster dose provides greater protection against the Omicron variant.”

- Advertisement -
- Advertisement -

Latest news

- Advertisement -
Previous article
What drives vaccine hesitancy?
Next article
Long-acting Antibody Treatment vs. Omicron Variant in Patients with Compromised Immune System

More Articles

Annual ‘Chalk the Walk’ Event Inspires Connection

Approximately 2.2 million Americans attempted suicide in 2024, according to the American Foundation for Suicide Prevention, while nearly 50,000 lives were lost to suicide. 

DHR Health’s Free Seminar on Breakthrough Treatment for Stroke Survivors, Sept. 19th

DHR Health’s Neuroscience Institute will host a free seminar for stroke survivors who want improved hand and arm movement as many stroke survivors experience impaired mobility and loss of function in the arm which can significantly affect their ability to   perform everyday activities.

STHS Heart’s Intensive Cardiac Rehab Program Earns AACVPR Recertification

Each year, more than 800,000 people in the United States experience a heart attack, according to the American Heart Association, and approximately one in four of those events are repeat occurrence

Newly Discovered Genetic Eye Disease Triggers Night Blindness and Tunnel Vision

Scientists identified a new vision condition linked to a gene already connected to a different vision-loss disease. While the previously identified disease causes loss of central vision, the new condition affects peripheral and night vision.
- Advertisement -